Migraine is common, disabling and badly served — millions of people manage it with little structured support. That makes it an attractive telehealth vertical, and a dangerous one to build carelessly. The difference between a good migraine service and a liability is triage and restraint: knowing which headaches are not migraine, and refusing to become a monthly triptan dispensary. Here is how to launch one safely.
Why migraine suits telehealth
Most people with migraine already know their pattern: the triggers, the warning signs, what has helped before. That makes structured remote care a good fit — a service can confirm the diagnosis, optimise acute treatment, add prevention where it is warranted, and review over time without a clinic visit for every episode.
The commercial model is a managed subscription rather than one-off supply, and the value is in the review and the safety-netting, not the dispatch. The critical caveat: a genuinely new or undiagnosed headache is not the same product as managing established migraine, and the two must not be treated alike.
Acute treatment: triptans and beyond
Acute migraine treatment is usually step-care. Options a prescriber may consider include:
- Triptans such as sumatriptan — some low-dose sumatriptan is available as a pharmacy (P) medicine under supervision, while other triptans and strengths are prescription-only.
- NSAIDs and simple analgesics, sometimes combined with a triptan.
- Anti-emetics such as metoclopramide or prochlorperazine, which help both nausea and absorption.
The right choice depends on attack severity, contraindications (triptans are cautioned in cardiovascular disease) and previous response — prescriber discretion applies. A safe service assesses that picture rather than defaulting everyone to the same triptan.
Preventive prescribing and its cautions
Where attacks are frequent, prevention is offered. Common preventers include propranolol, amitriptyline, topiramate and candesartan, with newer CGRP-targeted treatments generally reserved for specialist settings. Each carries its own cautions, and the assessment has to weigh comorbidities and patient preference.
Topiramate deserves particular care: it is teratogenic, and the MHRA has tightened safety measures around its use in anyone who could become pregnant, including pregnancy-prevention requirements. A remote service prescribing it must build those safeguards in, not treat it as a routine repeat. When in doubt, prescriber discretion and specialist referral apply.
The medication-overuse headache trap
The single biggest risk in a migraine supply model is medication-overuse headache (MOH). Using acute treatments — triptans or analgesics — on too many days each month can itself drive a chronic daily headache, and the widely cited thresholds sit around ten to fifteen days a month depending on the drug. A service that simply refills triptans on demand actively manufactures this problem.
So acute-treatment supply has to be capped and monitored, with frequency of use tracked and rising use triggering review rather than a bigger box. This is a design decision, not a nicety: build the limit into the system so it cannot be quietly overridden.
The defining risk of a migraine service is medication-overuse headache: refill triptans on demand and the supply model itself creates chronic daily headache. Acute-use frequency must be capped and monitored, with rising use triggering review — not a bigger box.
Red flags and when to refer
Migraine is a diagnosis of exclusion in the wrong context. Clinicians need clear red flags that take a patient out of the remote pathway and into urgent care: a sudden thunderclap headache, any new neurological deficit, a first severe headache over the age of 50, systemic features such as fever, or a headache that is simply the worst ever. These point away from migraine and toward emergencies.
An undiagnosed new headache should not be managed as migraine over an online form. The safe response is assessment and, where indicated, urgent referral — and documenting that decision. A service that treats every headache as migraine is not a migraine service; it is a hazard.
A service that treats every headache as migraine is not a migraine service; it is a hazard. Thunderclap onset, new neurological signs, a first severe headache over 50 — these leave the remote pathway and go to urgent care.
Building the review and supply model
The operational spine is diagnosis confirmation, a headache diary or equivalent monitoring, acute-use tracking with MOH limits, a preventive-review cadence, and hard safety-netting to urgent care. Wrap it in standard procedures so the same judgement applies to every patient, every time. Our guide to writing clinical SOPs covers how to make that consistent.
As with any prescribing vertical, the decision is build versus partner for the regulated layer. Identity, prescriber governance and dispensing are slow to build and fast to get wrong; see our launch checklist for the full sequence and verification for restricted medicines for the safeguards.
How PExpo supports a migraine launch
PExpo provides the regulated layer — registered dispensing, prescriber governance, pharmacovigilance and the patient record — so a brand can launch a migraine service on a compliant base, with the acute-use limits and safety-netting that make it defensible sitting on infrastructure built to run them.
You bring the brand and the patient experience; the higher-risk clinical plumbing is already in place. See our brand model for the scope and pricing for the commercials.
Migraine rewards operators who build for triage, review and restraint rather than supply on demand. Confirm the diagnosis, cap acute use against overuse headache, handle topiramate with the safeguards the MHRA requires, and safety-net hard. See our launch checklist and brand model for the operational detail.
Frequently asked questions
Can you prescribe triptans online in the UK?
Yes, where prescribing is led by clinical assessment. Some low-dose sumatriptan is available as a pharmacy medicine, while other triptans are prescription-only. A safe service checks contraindications such as cardiovascular disease, caps frequency of use against medication-overuse headache, and refers red-flag headaches to urgent care. Prescriber discretion applies.
What is medication-overuse headache?
Using acute migraine treatments — triptans or analgesics — on too many days each month can itself cause a chronic daily headache, with commonly cited thresholds around ten to fifteen days a month depending on the drug. A supply model must monitor and cap acute use rather than refilling on demand.
Is topiramate safe to prescribe remotely for migraine prevention?
Topiramate is teratogenic, and the MHRA has tightened safety measures around its use in anyone who could become pregnant, including pregnancy-prevention requirements. A remote service must build those safeguards in, and specialist referral may be more appropriate. Prescriber discretion applies.
